

March 14th, 2019  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director,  
President and Chief Executive Officer

**Notice of Instruction for Front-Loading Exercise of the 46<sup>th</sup> Stock Acquisition Rights  
(with Exercise Price Revision Clauses) Issued by way of Third Party Allotment**

TOKYO, Japan, March 14, 2019—Symbio Pharmaceuticals Limited (JASDAQ: 4582) announces that the instruction for front-loading exercise of the 46<sup>th</sup> stock acquisition rights, defined by the purchase agreement executed with EVO FUND, has been made today.

Our Business is progressing as originally planned and in a position where more capital is needed to further grow our business. In such situation, after considering our stock price and volume, we have come to a resolution to give this instruction from our belief that the front-loading exercise of the warrants would have relatively minimal impact to the market and the timing is such that there is high possibility to raise adequate capital to push forward our business.

We, as of today, confirm that we fulfilled such requirements for the front-loading exercise of the 46<sup>th</sup> stock acquisition rights to be made that we do not possess unpublished insider information and the 45<sup>th</sup> stock acquisition rights are not remaining.

(1) Name of stock acquisition rights	Symbio Pharmaceuticals Limited 46 <sup>th</sup> Stock Acquisition Rights
(2) Number of stock acquisition rights	15,000,000 units
(3) Date of instruction for front-loading exercise	March, 14th, 2019
(4) Date to start exercise	March, 15th, 2019 (Originally April 26th, 2019)

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Commit Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.